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Abstract
Background: GM1-gangliosidosis is a glycosphingolipid (GSL) lysosomal storage disease caused by a genetic deficiency of
acid b-galactosidase (bgal), which results in the accumulation of GM1-ganglioside and its asialo-form (GA1) primarily in the
CNS. Age of onset ranges from infancy to adulthood, and excessive ganglioside accumulation produces progressive
neurodegeneration and psychomotor retardation in humans. Currently, there are no effective therapies for the treatment of
GM1-gangliosidosis.
Methodology/Principal Findings: In this study we examined the effect of thalamic infusion of AAV2/1-bgal vector in adult
GM1 mice on enzyme distribution, activity, and GSL content in the CNS, motor behavior, and survival. Six to eight week-old
GM1 mice received bilateral injections of AAV vector in the thalamus, or thalamus and deep cerebellar nuclei (DCN) with
pre-determined endpoints at 1 and 4 months post-injection, and the humane endpoint, or 52 weeks of age. Enzyme activity
was elevated throughout the CNS of AAV-treated GM1 mice and GSL storage nearly normalized in most structures analyzed,
except in the spinal cord which showed ,50% reduction compared to age-matched untreated GM1 mice spinal cord.
Survival was significantly longer in AAV-treated GM1 mice (52 wks) than in untreated mice. However the motor
performance of AAV-treated GM1 mice declined over time at a rate similar to that observed in untreated GM1 mice.
Conclusions/Significance: Our studies show that the AAV-modified thalamus can be used as a ‘built-in’ central node
network for widespread distribution of lysosomal enzymes in the mouse cerebrum. In addition, this study indicates that
thalamic delivery of AAV vectors should be combined with additional targets to supply the cerebellum and spinal cord with
therapeutic levels of enzyme necessary to achieve complete correction of the neurological phenotype in GM1 mice.
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Introduction
GM1-gangliosidosis is a neurodegenerative lysosomal storage
disease caused by deficiency of acid b-galactosidase (bgal) [1]
leading to progressive accumulation of GM1-ganglioside in the
CNS [2]. Age of onset of the symptoms ranges from infancy to
adulthood and the severity of the clinical manifestations mostly
correlates with the levels of residual enzyme activity [3]. In the
most severe form of this disease (Infantile or Type I) biochemical
and neuropathological alterations have been documented in
utero [4,5]. Progressive neurologic deterioration, macular cherry
red spot, facial dysmorphism, hepatosplenomegaly, generalized
skeletal dysplasia and early death are common features of
the disease [3]. Currently there is no effective treatment for
GM1-gangliosidosis.
The available knockout mouse models replicate several clinical
and biochemical features of infantile GM1-gangliosidosis with low
levels of bgal activity (,4% of normal) and massive accumulation
of GM1-ganglioside and GA1 glycosphingolipid throughout the
CNS [6,7]. The bGal
2/2 (GM1) mice used in this study
accumulate abnormal levels of GM1-ganglioside as early as post-
natal day 5 [8], and reach several fold above normal by 3 months
of age [6,9]. This feature is associated with a progressively severe
CNS condition characterized by tremor, ataxia, abnormal gait and
ultimately paralysis of the hind limbs [6]. Studies on this mouse
model identified previously unknown molecular pathways that are
induced by GM1 accumulation and result in neuronal apoptosis
and neurodegeneration [10,11]. Defective lysosomal degradation
of GM1 was found to provoke the redistribution of this ganglioside
at the ER membranes, where it induces depletion of ER Ca
2+
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(UPR) and UPR-mediated apoptosis [11]. More recently it was
shown that GM1 accumulates specifically in glycosphingolipid-
enriched fractions (GEMs) of the mitochondria-associated ER
membranes, the sites of apposition between ER and mitochondria.
GM1 at the GEMs favors Ca
2+ flux between these organelles,
which results in mitochondrial Ca
2+ overload and activation of the
mitochondrial leg of apoptosis [10]. Neuronal apoptosis is
accompanied by neuroinflammation with increased microglial
activation, production of inflammatory cytokines, chemokines, and
inflammatory cell infiltration [12,13].
Currently there is no effective treatment for GM1-gangliosidosis
in children, although numerous therapeutic modalities have been
implemented in GM1 mice with somewhat encouraging results
[13,14].
Direct infusion of adeno-associated virus (AAV) vectors
encoding lysosomal enzymes into the brain parenchyma has
emerged as a viable strategy to create an in situ source of normal
enzyme in the brain [15]. A major obstacle to translation of the
promising results obtained in animal models is the number of
injections that may be needed to achieve global distribution of
enzyme throughout the human brain. Based on studies in a-
mannosidosis cats, it has been estimated that 40–60 injections of
AAV vector may be necessary to obtain global distribution of
lysosomal enzymes in the infant brain [16]. This large number
of injections makes the treatment extremely invasive and with
obvious risks. Therefore, alternative strategies are needed.
Previously we have shown that infusion of an AAV vector
encoding bgal into the cerebral lateral ventricles of neonatal
GM1 mice led to complete enzymatic and neurochemical
correction of the brain in these animals [17]. Since most human
patients are only identified after birth and newborn mice are
developmentally equivalent to a human fetus, we set out to
investigate a therapeutic approach that would be more relevant
to the situation in humans. Lysosomal enzymes are distributed in
the CNS from vector-transduced cells by axonal transport
[18,19,20,21] (among other mechanisms). One approach that
takes advantage of this property is to target gene delivery to
specific structures axonally connected to many areas of the brain.
AAV-mediated gene delivery to the ventral tegmental area, one
such structure, leads to widespread distribution of therapeutic
levels of a lysosomal enzyme throughout the mouse brain [22].
The thalamus as the major information relay center in the brain
receives and processes sensory, motor, limbic and arousal input
from various regions of the CNS and relays the information to
multiple brain structures including the cerebral cortex. It is one of
the most interconnected structures in the brain, and thus an
appealing target for gene delivery to achieve widespread
distribution of lysosomal enzymes via axonal transport. Also
AAV-mediated gene transfer to deep cerebellar nuclei (DCN)
appears to be an effective approach to deliver lysosomal enzymes
and growth factors to cerebellum and spinal cord [23,24]. Here
GM1 mice received bilateral infusions of AAV vector encoding
mouse bgal into the thalamus or thalamus and deep cerebellar
nuclei at six to eight weeks of age and we analyzed the effects of
this treatment on neurochemistry, motor performance over time
and survival. Our results show that AAV-mediated gene delivery
in adult GM1 mice increased bgal activity and reduced GM1-
ganglioside levels to nearly normal in the brain, but only ,50%
in the spinal cord. Although the motor performance of AAV-
treated GM1 mice remained comparable to that of untreated
GM1 mice, their survival was significantly extended with mice
receiving bilateral injections in thalamus and DCN surviving until
12 months of age.
Materials and Methods
Mice
GM1-gangliosidosis (GM1) mice were obtained from Dr.
Alessandra d’Azzo (St. Jude Children’s Research Hospital,
Memphis, TN) and have been described previously [6].
AAV Vector Design and Preparation
The design and production of AAV2/1-CBA-bgal vector
carrying the mouse lysosomal acid beta-galactosidase (bgal) cDNA
under the CBA promoter, which is comprised of the CMV
immediate-early enhancer fused to the chicken beta-actin
promoter, was described previously [17]. The plasmid pAAV-
ApoE4hAAT-bgal-W was constructed by replacing the CBA
promoter in the plasmid pAAV-CBA-bgal-W [17] with the hybrid
ApoE4/hAAT liver specific promoter (human alpha-1 antitrypsin
promoter fused to 4 copies of the apolipoprotein A enhancer [25]
(kindly provided by Dr. Valder Arruda, The Children’s Hospital
of Philadelphia, Philadelphia, PA). The AAV2/rh8-ApoE4hAAT-
bgal vector was prepared as described [26]. All vectors used in this
study carry the woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE).
Delivery of AAV vector to the brain
Six to eight week-old GM1 mice were anesthetized by
intraperitoneal injection of ketamine (125 mg/kg) and xylazine
(12.5 mg/kg) in 0.9% saline, and placed in a small animal
stereotaxic frame (Stoelting, Wood Dale, IL). An incision was
made over the skull, the periosteum removed and a burr hole was
made at the appropriate stereotaxic coordinates using a high-speed
drill (Dremel, Racine, WI). The noncompliant infusion system
used in these experiments for delivery of AAV vector was
assembled using a Harvard 22 syringe pump (Harvard Apparatus,
Holliston, MA) to drive a gas-tight Hamilton Syringe (Hamilton,
Reno, NV) attached to a 33-gauge steel needle (Hamilton) via 1/
16060.0200 ID PEEK tubing (Alltech, Deerfield, IL) and Luer
adapters (Amersham Biosciences). First the syringe and tubing
were filled with sterile mineral oil and then vector stock was
withdrawn into the needle and line. The needle assembly
(needle+Luer adapters) was fixed to the arm of the stereotaxic
frame. AAV2/1-CBA-bgal vector was infused (1 ml at 0.2 ml/min)
into the left thalamus (AP 22.0 mm, ML 21.5 mm relative to
bregma, and DV 22.5 mm from the brain surface). In subsequent
therapeutic efficacy experiments the AAV2/1-CBA-bgal vector
was infused (0.2 ml/min) bilaterally into the thalamus at two
depths (AP 22.0 mm, ML +/21.5 mm relative to bregma; and
23.5 and 22.5 mm from the brain surface; 1 ml per depth) (total
dose per mouse=4.8610
10 gc), or bilaterally into the thalamus
(as above) and deep cerebellar nuclei (AP: 26.3 mm; ML:
+/21.5 mm; DV 22.0 mm; 1 ml per side) (total dose per
mouse=7.2610
10 gc). In the PBS control group, age matched
GM1 mice received bilateral infusion of PBS into the thalamus
and deep cerebellar nuclei (same infusion rate and volume as
above). The needle was left in place for 2.5 min after the injection
was finished and then retracted halfway and left in place for an
additional 2.5 min before complete withdrawal. The incision was
closed with surgical staples, or colloidin, and the animal was
allowed to recover completely before being returned to the holding
room.
Behavioral Testing
Rotarod test. A rotarod apparatus, consisting of a knurled
dowel fixed 10 cm above bedding was used to measure motor
coordination and balance as previously described [27]. After a 3-
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at 1, 2.5, 4, and 6 months post injection. Mice were placed on the
rotating dowel at 20 rpm, indicating the start time for the trial. A
30-second interval was allowed between the two trials at the given
speed. The maximum time allowed on the bar for each trial was
60 seconds. The trial was terminated when the mouse fell off the
bar or at 60 seconds.
Open-field test. Locomotor activity and rearing events in the
mice were assessed using the SmartFrame Cage Rack System
(Kinder Scientific, San Diego, CA). Infrared beams along the
frame of the system track mouse movement in the cage with
respect to location, distance, and rearing capabilities. Mice were
placed in the center of the open-field apparatus and behavior was
measured for 15 minutes. The data was analyzed using the
MotorMonitor software (Kinder Scientific, San Diego, CA).
Locomotor activity was measured as the distance traveled (in
inches) and rearing events were measured as the number of times
the mouse stood on its hind legs. Comparisons were narrowed to
the first 5 minutes when we found significant differences between
untreated GM1 and HZ mice, as previously shown [13].
Visual evoked potentials
Visual evoked potentials (VEPs) were recorded in AAV-treated
GM1 mice (AAV-T and AAV-TC groups; n=3 for each group) at
9–10 months of age. The VEPs were also recorded from untreated
heterozygote (n=2) and GM1 (n=4) mice at 10 months and 7–8
months of age, respectively, according to previously described
methods [28]. Briefly, the mice were dark-adapted overnight and
then anesthetized. The left pupil was dilated and responses were
elicited with 10-ms full-field flashes of white light presented every
second at 3.4 log ft.L. VEPs were monitored with subdermal
electrodes in the scalp over the visual cortex as the positive
electrode and over the frontal cortex as the reference. The
responses were collected as previously described [28]. The
consecutive waveforms were averaged (n=100) after suppressing
the heart-beat artifact with an adjustable low-pass digital filter (cut-
off at 50–70 Hz) and rejecting waveforms containing movement
artifacts.
All animal experiments were carried out with ethical committee
approval in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care Committees at the
Massachusetts General Hospital (Approved Protocol #:
2003N000343/3) and Boston College (Approved Protocol #:
2009-014-01).
Tissue Preparation
Mice were killed by CO2 asphyxiation at 1 or 4 months post-
injection or at the humane endpoint defined by .20% loss in
maximal body weight. The brains were harvested at 1 and 4
months post injection and at the humane endpoint. The left
hemisphere of the brain was embedded in tissue freezing medium
(Triangle Biomedical Sciences, Durham, NC) and rapidly frozen
in a 2-methylbutane/dry-ice bath. Consecutive 20-mm thick
coronal cryosections were prepared and stored at 280uC. One
series of frozen sections representing the entire brain from AAV-
treated GM1 mouse, or control non-injected GM1 mice was fixed
for 10 min in 0.25% glutaraldehyde in phosphate buffered saline
(PBS) at room temperature followed by two washes in PBS.
Sections were stained for bgal using X-gal solution [5 mM
K4Fe(CN)6, 5 mM K3Fe(CN)6, 2 mM MgCl2, 1 mg/ml 5-bromo-
4-chloro-3-indolyl-D-galactosidase (X-gal) in PBS, pH 5.0 as
described [17].
The right hemisphere of the brain was grossly dissected into
cortex, cerebellum, brainstem plus sub-cortical structures (Bs+ScS;
subcortical structures included midbrain, thalamus, hypothalamus,
hippocampus and striatum), and rapidly frozen on dry ice. The
right hemisphere was used for analysis of bgal enzymatic activity
and lipids. In addition, the spinal cord was divided into 0.5 cm
transverse sections. Alternating sections were collected and
analyzed for GSL storage. The values obtained in untreated and
PBS-treated GM1 mice were indistinguishable from each other
and as a result, were pooled together.
b-Galactosidase Assay
Total b-galactosidase activity was determined using 4-methy-
lumbelliferyl-b-D-galactopyranoside as the synthetic fluorogenic
substrate, specific for b-galactosidase as previously described [9].
Total b-galactosidase activity was determined by measuring the
release of 4-methylumbelliferone at excitation 360 nm, emission
460 nm on a SpectraMax M5 plate reader (Molecular Devices,
Sunnyvale, CA) and normalized to total protein concentration.
Isolation and Purification of Glycosphingolipids
Total Lipid Extraction. Total lipids were extracted as
previously described [29]. Briefly, frozen brain samples were
lyophilized and the dry weights were measured. Total lipids were
extracted from the lyophilized brain samples in a solution of
chloroform (CHCl3):methanol (CH3OH) and distilled water
(dH2O). The samples were placed on a magnetic stirrer at room
temperature for at least 8 hours and then centrifuged for
15 minutes at 1200 g. The supernatant was collected and the
pellet was washed with CHCl3:CH3OH (1:1 by volume) and
centrifuged as before. The combined supernatants were converted
to a CHCl3:CH3OH:dH2O ratio of 30:60:8 (solvent A).
Column Chromatography. Neutral and acidic lipids were
separated using DEAE-Sephadex (A-25, Pharmacia Biotech,
Upsala, Sweden) column chromatography as previously described
[30]. DEAE-Sephadex was prepared in bulk by washing the resin
three times with solvent B (CHCl3:CH3OH:0.8 M Na acetate,
30:60:8 by volume), equilibrating in solvent B overnight, followed
by washing three times with solvent A (CHCl3:CH3OH:dH20,
30:60:8 by volume) until neutral. The total lipid extract, suspended
in solvent A, was applied to a DEAE-Sephadex column. The
column was washed twice with solvent A and the entire neutral
lipid fraction, consisting of the initial eluent plus washes, was
collected. This fraction contained cholesterol, phosphatidylcholine,
phosphatidylethanolamine and plasmologens, sphingomyelin, and
neutral GSLs to include cerebrosides and asialo-GM2 (GA2). Next,
acidic lipids were eluted from the column with solvent B.
Ganglioside Purification. The acidic lipid fraction contain-
ing gangliosides was dried by rotary evaporation and transferred to
a 15 mL graduated conical glass tube. Water was added and the
mixture was inverted, vortexed, and centrifuged for about
15 minutes at 12006g to partition gangliosides into the upper
phase [31]. The upper aqueous phase was removed and the lower
organic phase was washed once with Folch ‘pure solvent upper
phase’ (CHCl3:CH3OH:dH20, 3:48:47 by volume).
Resorcinol Assay. An aliquot of the ganglioside fraction
(Folch upper phase) was evaporated and analyzed for sialic acid
content using a modified resorcinol assay [32]. N-acetylneuraminic
acid (Sigma # A9646, St. Louis, MO, USA) (1, 3, and 6 mg) was
used as an external standard. Samples were dissolved in 1 mL of
resorcinol reagent (40 mL concentrated HCl, 0.125 mL 0.1 M
copper sulfate, 5 mL 2% resorcinol stock, brought to 50 mL with
distilled water):dH2O (1:1 by volume), boiled for 17 minutes, and
then cooled in an ice bath. Butyl acetate:1-butanol (1.5 mL, 85:15
AAV Thalamic Gene Delivery
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vortexed and centrifuged at 12006g. The supernatant was then
carefully removed and analyzed in crystal cuvettes at 580 nm
in the Shimadzu UV-1601 UV-visible spectrophotometer
(Shimadzu, Kyoto, Japan).
Base Treatment and Desalting. After removing aliquots for
the resorcinol assay, the ganglioside fraction was evaporated under
a stream of nitrogen and treated with mild base (1 mL of 0.5 M
NaOH) in a shaking water bath at 37uC for 1.5 hours. Base and
salts were separated from the gangliosides using a modification of a
previously described method [33]. Briefly, the sample was applied
to a C18 reverse-phase Bond Elute column (Varian, Harbor City,
CA, USA) and then the column was washed with dH2O to remove
salts. Gangliosides were eluted from the column with CH3OH and
then followed CHCl3:CH3OH (1:1 by volume). Samples were
evaporated under nitrogen, re-susupended in CHCl3:CH3OH (1:1
by volume), and then stored at 4uC.
Acidic Phospholipid Purification - After the ganglioside fraction
(Folch upper phase) was transferred, the acidic phospholipid
fraction (Folch lower phase) was evaporated under a stream of
nitrogen and resuspended in CHCl3:CH3OH (1:1 by volume).
This fraction contained fatty acids, cardiolipin, phosphatidylserine,
phosphatidylinositol, sulfatides.
Neutral Lipid Purification. Neutral lipids were dried by
rotary evaporation and resuspended in CHCl3:CH3OH (2:1 by
volume). To further purify GA1, an aliquot of the neutral lipid
fraction was evaporated under a stream of nitrogen, base treated
with 1 N NaOH, and Folch partitioned as described previously
[8,30]. The Folch lower phase containing GA1 was evaporated
under a stream of nitrogen and re-suspended in CHCl3:CH3OH
(2:1 by volume).
Analysis of Glycosphingolipids by HPTLC
All lipids were analyzed qualitatively by high-performance thin-
layer chromatogram (HPTLC) according to previously described
methods [8,30]. To enhance precision, an internal standard (oleoyl
alcohol) was added to the neutral and acidic lipid standards and
samples as previously described. Purified lipid standards were
either purchased from Matreya Inc. (Pleasant Gap, PA, USA),
Sigma (St. Louis, MO, USA), or were a gift from Dr. Robert Yu
(Medical College of Georgia, Augusta, GA, USA). Lipids were
spotted on 10620 cm Silica gel 60 HPTLC plates (E. Merck,
Darmstadt, Germany) using a Camag Linomat V semi-automatic
TLC spotter (Camag Scientific Inc., Wilmington, NC, USA).
For gangliosides and GA1, the HPTLC plates were developed
by a single ascending run with CHCl3:CH3OH:dH2O (55:45:10
by volume for gangliosides and 65:35:8 by volume for GA2)
containing 0.02% CaCl22H2O. The plates were sprayed with
either resorcinol-HCl or orcinol-H2SO4 reagent and heated on an
aluminium block heater at 105uC for approximately 30 minutes to
visualize gangliosides or GA1, respectively [32].
For neutral and acidic phospholipids, the plates were developed
to a height of either 4.5 cm or 6 cm, respectively with chloroform:
methanol: acetic acid: formic acid: water (35:15:6:2:1 by volume),
and then both were developed to the top with hexanes: diisopropyl
ether: acetic acid (65:35:2 by volume) as previously described [34].
Neutral and acidic phospholipids were visualized by charring with
3% cupric acetate in 8% phosphoric acid solution, followed by
heating in an oven at 165uC for 7 minutes.
The percentage distribution and density of individual bands was
determined as previously described [8]. Briefly, the HPTLC plates
were scanned on a Personal Densitometer SI with ImageQuant
software (Molecular Dynamics) or on a ScanMaker 4800 with
ScanWizard5 V7.00 software (Microtek). The total brain gangli-
oside distribution was normalized to 100% and the percentage
distribution values were used to calculate sialic acid concentration
of individual gangliosides as we previously described [35]. The
density value for GA1 was fit to a standard curve of known lipid
concentration and used to calculate concentration. For the neutral
and the acidic phospholipids, each lipid was normalized to an
internal standard (oleoyl alcohol) and its concentration was
quantified using a standard curve of each respective lipid. All
Figure 1. Distribution of bgal in the brain after AAV1-mediated thalamic gene delivery. One ml of AAV2/1-CBA-mbgal vector (4.12610
13
gc/ml) was injected into the left thalamus of 6–8 week-old GM1 mice. (A–F) One month later the brain was analyzed for bgal distribution by X-gal
histochemical staining. bgal staining was evident throughout the ipsilateral hemisphere. Arrowhead in (C) indicates the ipsilateral perirhinal and
piriform cortices where bgal staining is less intense than elsewhere in the cortex in the same coronal plane. (G–I) Detection of vector mRNA by
radioactive in situ hybridization. (G), (H), (I) show the signal detected in tissue sections adjacent to those stained for bgal activity with X-gal shown in
(C), (D), and (E), respectively. Arrowheads in (C), and (E) indicate the perirhinal, piriform and entorhinal cortices. Scale bars in (A–F) represent 1mm.
doi:10.1371/journal.pone.0013468.g001
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Real-Time PCR
RNA was isolated from cerebrum, cerebellum, brainstem plus
sub-cortical structures (Bs+ScS), and spinal cord using Trizol
reagent (Invitrogen, Carlsbad, CA), and first-strand cDNA synthesis
was performed using Omniscript reverse transcriptase (Qiagen,
Valencia, CA) according to manufacturers’ instructions. Real-time
PCR analysis of disease marker gene expression was performed
using Taqman Gene Expression Assays (Applied Biosystems, Foster
City, CA.) for TNFa, FAS, MIP-1a,, MHC class II, F4/80, and
GAPDH as housekeeping gene.PCR was performed on a 7500 Fast
Real-time PCR system (Applied Biosystems) in Fast Mode. Gene
expression levels were normalized to GAPDH (DCt) and then
compared to heterozygote (HZ) levels using the formula 2
DDCt to
calculate fold over HZ level for each gene. Error associated with
fold change was calculated using the following formula [36]:
SEMfoldchange~
(ln2)(stdevDDCt)(2({DDCt))
ﬃﬃﬃ
n
p .
Statistical Analysis
Data were analyzed by one-way analysis of variance or
Student’s t-test to calculate statistical significance between
untreated GM1 mice, AAV-treated GM1 mice, and control HZ
mice using Statview 5.0, or Microsoft Excel software.
Results
Thalamic infusion of AAV vector in adult GM1 mice
results in widespread distribution of bgal in the brain
We injected 1 ml of AAV2/1-CBA-mbgal vector (4.12610
13
gc/ml) into the left thalamus of 6–8 week-old GM1 mice and one
month later analyzed lysosomal acid beta-galactosidase distribu-
tion in the brain by X-gal histochemical staining of tissue sections
(Fig. 1). The highest staining intensity (dark blue) was observed in
dorsal and lateral thalamus, but intense bgal staining was observed
in retrosplenial, visual, somatosensory, and auditory cortices.
Interestingly there was a clear boundary of enzyme distribution in
the cortex with lower bgal staining in perirhinal, piriform and
entorhinal cortices (arrowheads in Fig. 1). In anterior regions of
the brain (Fig. 1A) we found that bgal staining declined from the
cingulate cortex to dorsolateral regions of the cortex (motor and
somatosensory). In the striatum the most intense bgal staining was
associated with the dorsal region (Fig. 1A). ISH analysis showed
that AAV-transduced cells were present in dorsal and lateral
thalamic nuclei only (Fig. 1G–I) and the signal intensity correlated
with areas in the brain (thalamus) that reacted most strongly with
Figure 2. b-galactosidase distribution in CNS of GM1-gangliosidosis mice after intraparenchymal infusion of AAV2/1-bgal vector. Six
to eight week-old GM1 mice received bilateral injections of AAV2/1-bgal vector (1.2610
13 gc/ml) into the thalamus (AAV-T; light gray bars), or
thalamus and deep cerebellar nuclei (AAV-TC; dark gray bars). Age matched heterozygote (white bars) and untreated GM1 mice (black bars) were
used as controls. Mice were sacrificed at 1, and 4 months post-infusion and at the humane endpoint (Endpoint). (A) The left brain hemisphere was
used for histological analysis of bgal distribution by X-gal staining at pH 5.0. Representative sections from an AAV-TC GM1 mouse sacrificed at 4
months post-injection are shown. Scale bar=1 mm. bgal activity was determined by 4MU assay in (B) cortex, (C) cerebellum, (D)
brainstem+subcortical structures (Bs+ScS), and (E) spinal cord at 1 (1M) and 4 (4M) months post-injection, and at the humane endpoint (Endpoint).
Error bars correspond to standard error of the mean. n.d. – not determined.
doi:10.1371/journal.pone.0013468.g002
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apparent in the ipsilateral cortex.
Intraparenchymal infusion of AAV vector in adult GM1
mice results in sustained bgal expression throughout the
CNS
Disease progression in the GM1 mouse model is associated with
microgliosis, production of inflammatory cytokines and chemo-
kines, up-regulation of inflammatory markers, and inflammatory
cell infiltration [12,13]. Beside the thalamus and hypothalamus,
these alterations are also detected prominently in the spinal cord
and cerebellum. As delivery of lysosomal enzymes to these
structures can be achieved by injection of AAV vectors into the
deep cerebellar nuclei [23], we included a group of GM1 mice
injected bilaterally in the thalamus and deep cerebellar nuclei.
Also since GM1 mice are bgal mRNA negative [6], we tested a
strategy previously used in the Niemann-Pick mouse to prevent
confounding effects of a potential immune response against AAV-
produced enzyme in the brain [37]. This approach consists of an
intravenous infusion of a second AAV vector encoding the
respective enzyme from a liver-specific promoter prior to
intracranial injection of the test AAV vector encoding the same
enzyme.
We injected 6–8 week-old GM1 mice intravenously (i.v.) with
3610
11 gc of AAV2/rh8-ApoE4hAAT-bgal vector via the tail
vein. Two weeks later we performed bilateral injections of AAV2/
1-CBA-bgal vector (1.2610
13 gc/mL) into the thalamus (AAV-T
group: n=23; Total dose=4.8610
10 gc); or bilateral injections
into the thalamus and deep cerebellar nuclei (AAV-TC group:
n=22; Total dose=7.2610
10 gc). As controls we included age
matched GM1 mice infused i.v. with AAV2/rh8-ApoE4hAAT-
bgal followed by intracranial injection of PBS in thalamus and
cerebellum (n=22), age matched untreated GM1 (n=22), and
HZ (n=24) mice. Mice were sacrificed at 1 and 4 months post-
injection, or at the humane endpoint defined by .20% loss in
maximum body weight achieved by each mouse. bgal activity in
the serum of GM1 mice at one month after tail vein injection was
25% of the level measured in the serum of age-matched naı ¨ve HZ
mice.
bgal enzymatic activity in the CNS of treated and control mice
was analyzed both qualitatively and quantitatively (Fig. 2). X-gal
staining of brain sections showed widespread bgal activity
throughout the brain in both groups of AAV-treated GM1 mice
(Fig. 2A). The bgal distribution pattern in the brain remained
essentially unchanged over time (data not shown). In the
cerebellum intense bgal staining was observed only in AAV-TC
GM1 mice (Fig. 2A). bgal activity against 4MU substrate was more
than 10-fold higher than the enzyme levels in HZ mice (white bars
in Fig. 2) in cortex and brainstem+sub-cortical structures (Bs+ScS)
from both groups of AAV-injected GM1 mice (gray bars in
Figs. 2B, C). bgal activity in the cerebellum of AAV-T GM1 mice
was restored to HZ values by 4 months post-injection and showed
a slight increase at the final endpoint (light gray bars, Fig. 2D). In
contrast, in the cerebellum of AAV-TC GM1 mice bgal activity
was .10-fold higher than in HZ cerebellum at 1 month post-
injection and remained elevated for the duration of the experiment
(dark gray bars, Fig. 2D). In AAV-T GM1 mice, bgal activity in
the spinal cord reached a maximum of 82% of HZ levels at 4
months post-injection and then declined to ,35% at the final
endpoint (light gray bars, Fig. 2E). In AAV-TC GM1 mice, bgal
activity in the spinal cord remained essentially stable after 4
months post-infusion at ,53% of HZ level (dark gray bars,
Fig. 2E). The bgal activity in the CNS of PBS-injected GM1 mice
was indistinguishable from that in age matched untreated GM1
controls (black bars, Fig. 2) at about 1–2% of HZ levels.
Sustained reduction in GM1-ganglioside content in the
CNS of AAV-treated GM1 mice
We next analyzed the same CNS regions from all groups of
mice and time points for the distribution of individual gangliosides
by high-performance thin layer chromatography (HPTLC) (Fig. 3).
The qualitative and quantitative distributions of individual
gangliosides in cortex, brain stem and subcortical structures
(Bs+ScS), cerebellum, and spinal cord at 4 months post-injection
are shown in Fig. 3A–H and Tables S1, S2, S3, S4, S5, S6, S7, S8,
S9, S10, S11. As expected, GM1-ganglioside content in untreated
or PBS-injected GM1 mice increased with age in all regions
analyzed (black bars in Fig. 3A, C, E, G – lane 2). In contrast,
GM1-ganglioside levels were dramatically reduced in both groups
of AAV-treated GM1 mice (light and dark gray bars in Fig. 3). In
AAV-T GM1 mice reductions in GM1-ganglioside content ranged
from a minimum of 31.6% (spinal cord at 1 month post-injection)
to a maximum of 86.4% (cerebral cortex at 4 months post-
injection) compared to the levels measured for the same structures
in age-matched untreated GM1 mice. In AAV-TC GM1 mice
GM1-ganglioside content was reduced from a minimum of 44%
(spinal cord at 1 month post-injection) to a maximum of 93.5%
(cerebellum at 4 months post-injection) relative to the levels
measured for the same structures in age-matched untreated GM1
mice. However, GM1-ganglioside levels in both groups of AAV-
treated mice remained consistently higher than levels in HZ mice,
with the exception of Bs+ScS at 4 months post-injection in both
groups, and the cerebellum in AAV-TC GM1 mice (Fig. 3F and
Tables S5, S7, and S8). By the humane (AAV-T) or experimental
(AAV-TC) endpoint the GM1-ganglioside content in all structures
analyzed was higher than normal levels in control HZ mice
(Fig. 3B, D, H – Endpoint light and dark gray bars). Additional
injection of AAV vector into the deep cerebellar nuclei had a
significant impact on the biochemical outcome in the cerebellum,
but only a marginal effect on the spinal cord GM1-ganglioside
content compared to thalamic injection alone.
An interesting observation was made when analyzing the
distribution of individual gangliosides following intracranial AAV
treatment. At 1 month post-injection, GM2- and GM3-ganglio-
sides were detected by HPTLC in all regions analyzed (Tables S1,
S4, S6, S9). However, at 4 months post-injection and at endpoint,
GM2- and GM3-gangliosides were no longer present.
Ganglioside GD3, a minor glycolipid in adult mouse CNS [38],
was absent in the cortex of all mice (Tables S1, S2, S3), but present
in Bs+ScS, cerebellum, and spinal cord (Tables S4, S5, S6, S7, S8,
Figure 3. Biochemical quantification of GM1-ganglioside content in the CNS of AAV-treated GM1 mice by HPTLC. Gangliosides were
isolated from (A, B) cortex, (B, C) cerebellum, (D, E) brainstem+subcortical structures (Bs+ScS), and (F, G) spinal cord of heterozygote (HZ, white
bars), untreated GM1 (1, black bars), PBS-treated GM1 (2), AAV-T GM1 (3, light gray bars), and AAV-TC GM1 (4, dark gray bars) mice. (A, C, E, G)
Representative chromatograms showing the qualitative distribution of gangliosides at 4 months post-injection. The amount of gangliosides spotted
per lane was approximately 1.5 mg sialic acid. The individual gangliosides were labeled according to the nomenclature system of Svennerholm (left
side of the chromatograms) [32]. (B, D, F, H) Mean concentration of GM1-ganglioside in each region of the CNS at 1 month (1M), 4 months (4M) post-
injection, and at the humane or experimental endpoint (Endpoint) are shown. Error bars represent 1 SEM. n.d. – not determined.
doi:10.1371/journal.pone.0013468.g003
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cerebellum, and spinal cord of untreated GM1 mice compared
to age-matched naı ¨ve HZ mice (Tables S4, S5, S6, S7, S8, S9,
S10, S11). In AAV-T and AAV-TC mice the ganglioside GD3
levels were increased over those in age-matched untreated GM1
mice (Tables S4, S5, S6, S7, S8, S9, S10, S11), and in some
instances close to levels found in HZ mice (e.g. Bs+ScS and
cerebellum 4 months – Tables S5 and S8).
Intracranial AAV treatment had no other major effect on the
distribution or content of the other individual gangliosides
analyzed.
Sustained reduction in GA1 glycosphingolipid in the CNS
of AAV-treated GM1 gangliosidosis mice
We analyzed the same regions of the CNS for all groups and
time points for GA1 content because of the concomitant
accumulation of this GSL in GM1 mice [6] (Fig. 4). As expected,
GA1 levels were significantly reduced in all CNS regions and time
points analyzed (p,0.01) for both groups of AAV-treated GM1
mice (light and dark gray bars in Fig. 4) compared to age matched
untreatedGM1mice(blackbarsinFig.4).InAAV-TGM1 micethe
lowest levels of GA1 were achieved at 4 months post-injection
(Fig.4B,D,H–4Mlightgraybars),butatendpoint,theGA1content
had increasedto 1.260.52, 2.5661.24, and 1.8860.71 mg/100 mg
dry tissue weight in cortex, cerebellum, and spinal cord, respectively
(Fig. 4B, D, H – Endpoint light gray bars). Also in AAV-TC GM1
mice, the lowest levels of GA1 were achieved at 4 months post-
injection(Fig.4B,D,H–4M;darkgraybars=0),albeititwaspresent
in the spinal cord (Fig. 4H–4M; dark gray bar). At endpoint (52
weeksofage),GA1remainedundetectableinthecerebellum(Fig.4C
– Endpoint; dark gray bar=0), but had increased to 0.5960.01, and
1.4960.14 mg/100 mg dry tissue weight in both the cortex, and
spinal cord (Fig. 4B, G – Endpoint; dark gray bars). In untreated
GM1 mice at the humane endpoint, GA1 levels were 7.1560.47,
5.8460.39, 3.2360.21 mg/100 mg dry tissue weight in cortex,
cerebellum, and spinal cord, respectively (Fig. 4B, D, and H –
Endpoint; black bars).
Cerebrosides are partially restored in the cortex of AAV-
treated adult GM1 Mice
Cerebrosides are myelin-enriched lipids, and changes in their
content in the CNS correlate with relative amount of myelin
[39,40]. The concentration of cortical cerebrosides for all groups
at 1 and 4 months post-injection are shown in Table 1. In naı ¨ve
and PBS-treated GM1 mice there was a statistically significant
decrease in concentration of cerebrosides for both time points
compared to HZ mice (p,0.05). This is consistent with previous
findings of reduced myelin in animal models and in patients with
GM1-gangliosidosis [41,42,43]. The concentration of cerebrosides
in both AAV-treated groups at 1 month post-injection was
comparable to that in naı ¨ve and PBS-treated GM1 mice. At 180
days of age, or 4 months post-injection, the concentration of
cerebrosides was significantly greater in AAV-T GM1 mice than
in naı ¨ve or PBS-treated GM1 mice. In AAV-TC GM1 mice the
concentration of cerebrosides remained stable between the two
time points, but below the levels in HZ control mice.
Effect of AAV treatment on disease marker gene
expression
Neurodegeneration in GM1 mice was shown to be the result of
GM1-mediated activation of both the UPR and the mitochondrial
apoptotic pathway [10,11]. Neuronal cell death elicits a neuroin-
flammatory process characterized by up-regulation of cytokines,
chemokines, inflammatory cell markers, and microglial activation
[12,13]. Thus we analyzed the mRNA expression levels of some
disease marker genes associated with inflammation, namely TNF-
a, Fas, MIP-1a, F4/80 in the cortex, cerebellum, Bs+ScS, and
spinal cord of mice sacrificed at the humane endpoint (untreated
GM1 mice, PBS-treated GM1 mice, AAV-T GM1 mice), or 52
weeks of age (AAV-TC GM1 mice, and heterozygote mice) (Fig. 5).
As expected most marker genes were elevated in untreated GM1
mice compared to naı ¨ve heterozygote mice, and in some instances
such as MIP-1a by more than 100-fold (Fig. 5C, black bars). In
AAV-T and AAV-TC GM1 mice there were statistically
significant decreases in expression levels in some of the structures
analyzed (asterisks in Fig. 5, p,0.05), but seldom to levels
comparable to those in heterozygote control mice.
Effect of AAV treatment on motor performance of GM1
mice
We used rotarod and open field tests to assess the motor
performance of AAV-treated GM1 and control mice at different
time points after injection (Fig. 6). Rotarod testing of all animals
prior to intracranial injection of AAV vector showed comparable
performance for all groups of mice (Fig. 6A). Mice were
subsequently tested at 1, 2.5, 4, and 6 months post-injection.
The performance of either group of AAV-treated GM1 mice
(AAV-T and AAV-TC) declined over time, and was indistinguish-
able from that of control untreated GM1 mice (Fig. 6A). The
Figure 4. Biochemical quantification of GA1 content in the CNS of AAV-treated GM1 mice by HPTLC. GA1 isolated from (A, B) cortex, (B,
C) cerebellum, (D, E) brainstem + subcortical structures (Bs+ScS), and (F, G) spinal cord of heterozygote (HZ, white bars*), untreated GM1 (1, black
bars), PBS-treated GM1 (2), AAV-T GM1 (3, light gray bars), and AAV-TC GM1 (4, dark gray bars) mice. (A, C, E, G) Representative chromatograms for 4
months post-injection are shown. The amount of sample spotted per lane was approximately equivalent to 0.2 mg tissue dry weight. (B, D, F, H)
Mean concentration of GA1 glycosphingolipid represented as mg of GA1/100 mg dry tissue weight (dw) for each region of the CNS at 1 month (1M),
4 months (4M) post-injection, and at the humane or experimental endpoint (Endpoint) are shown. Error bars represent 1 SEM. n.d. – not determined;
* White bars=0.
doi:10.1371/journal.pone.0013468.g004
Table 1. Concentration of cortical cerebrosides in adult GM1
Mice
a.
Genotype Treatment 90 days of age 180 days of age
bgal+/2 - 2.4360.14 2.5460.14
bgal2/2 - 1.4560.15
# 1.3960.07
#
bgal2/2 PBS 1.4060.25
# 1.2560.05
#
bgal2/2 AAV-T 1.5960.10 2.0660.27*
bgal2/2 AAV-TC 1.7360.16 1.7960.19
aConcentration expressed as mg/100 mg dry weight. Values represent mean 6
SEM, where 3 independent samples were analyzed per group.
#Indicates that the value is significantly different from that in untreated bgal+/2
mice at P,0.05.
*Indicates that the value is significantly different from that in untreated bgal2/2
mice at P,0.01.
doi:10.1371/journal.pone.0013468.t001
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the duration of the experiment. Open-field testing was performed
at 2.5 and 4 months post-injection to measure locomotor (Fig. 6B)
and rearing activity (Fig. 6C). At 2.5 months post-injection the
locomotor activity of both groups of AAV-treated GM1 mice was
greater than untreated GM1 controls (Fig. 6B, 2.5M - black bar),
but statistical significance (p,0.05) was only achieved in AAV-T
GM1 mice (Fig. 6B, 2.5M – light gray bar). By 4 months post-
injection the locomotor activity of AAV-treated GM1 mice
declined and was indistinguishable from untreated GM1 control
mice (Fig. 6B, 4M). The locomotor activity of untreated GM1
mice increased between the two time points (Fig. 6B, black bars,
p,0.01), while that of HZ controls decreased (Fig. 6B, white bars,
p,0.05). Although the number of rearing events in AAV-treated
GM1 mice (Fig. 6C, gray bars) was consistently higher than in
untreated GM1 mice controls (Fig. 6C, black bars), this difference
was significant only in AAV-T GM1 mice at 2.5 months post-
injection (p,0.05).
Effect of AAV treatment on Visual Evoked Potentials in
GM1 mice
GM1 mice older than 6 months display visual abnormalities
characterized by normal electroretinograms but subnormal
visually evoked potentials (VEP) [28]. We analyzed VEPs in
AAV-treated GM1 mice at 10–11 months of age, and age
matched untreated control HZ mice (Fig. 7). Untreated GM1 mice
were analyzed at 7–8 months of age, and presented subnormal
VEPs (Fig. 7C) compared to wild type (Fig. 7A) and HZ (Fig. 7B)
mice. AAV-treated GM1 mice showed some response to the visual
stimulus (Fig. 7D, E), albeit with considerable variability among
animals within each group (gray lines in Fig. 7D, E represent the
VEP of each individual animal in the group). The VEP data also
Figure 5. Disease marker gene expression in the CNS of AAV-treated GM1 mice. Untreated GM1 mice (black bars), and AAV-T GM1 mice
(light gray bars) were sacrificed at the humane endpoint defined by .20% loss in body weight, or at 52 weeks of age for AAV-TC GM1 mice (dark gray
bars), and HZ mice (white bars). Total RNA was isolated from cerebrum (c), cerebellum (Cb), brainstem+subcortical structures (Bs+ScS), and spinal
cord (sc) and used for real-time PCR quantification of TNF-a (A), Fas (B), MIP-1a (C), and F4/80 (D) expression levels. Average fold induction over
normal (HZ levels) was calculated for each tissue. Error bars correspond to 1 SEM. * indicates statistical significance with a p-value,0.05 in Student’s t-
test.
doi:10.1371/journal.pone.0013468.g005
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75 msec) for AAV-treated mice. These data suggest that AAV-
treated GM1 mice retained some degree of visual functionality
past 6 months of age. Histological analysis of the eye at the
humane endpoint (untreated GM1 and AAV-T GM1 mice), or 1
year of age (heterozygote mice, and AAV-TC GM1 mice) showed
evidence of some bgal activity in the retinal ganglion cell layer
(GCL) in both groups of AAV-injected GM1 mice compared to no
detectable activity in the retinas of untreated GM1 mice (Fig. 8).
Effect of AAV treatment on survival
In addition to sacrificing mice at different time points after
treatment for biochemical and histological analyses, we allowed a
subset of animals from each group (n=8–12 animals per group) to
survive until the humane endpoint defined by .20% loss in body
weight. The median survival for untreated and PBS-injected GM1
mice was 38 and 37 weeks post-treatment, respectively (Fig. 9),
while the median survival time for AAV-T GM1 mice was
significantly increased to 45 weeks (p,0.05, Log-Rank test). All
but one AAV-TC GM1 mouse (n=8) survived until the 52-week
experimental endpoint (p,0.001, Log-rank test), despite their
poor performance in motor tasks. Although these animals never
reached the humane endpoint as defined above, they displayed
signs of disease such as tremor, and difficulty in moving the hind
limbs at the experimental endpoint.
Discussion
Previously, we had shown that a single AAV injection into the
cerebral lateral ventricles of neonatal GM1 mice was sufficient to
correct the neurochemical phenotype [17]. In this study, we
examined the therapeutic efficacy of an AAV2/1 vector encoding
mouse bgal infused bilaterally into the thalamus, or thalamus and
deep cerebellar nuclei of adult GM1 mice. This intraparenchymal
infusion approach led to sustained high-level expression of bgal in
many of the CNS structures analyzed, and dramatic reductions in
GM1-ganglioside and GA1 content. Surprisingly the motor
performance of AAV-treated GM1 mice declined over time at a
rate similar to that of untreated GM1 mice. Nonetheless, the
median survival of both groups of AAV-treated mice was
significantly increased compared to untreated GM1 mice.
Our results show that thalamic delivery of an AAV2/1 vector
encoding mouse bgal is an effective approach to achieve
widespread distribution of therapeutic levels of this enzyme in
the adult GM1 mouse brain. The distribution of bgal in the brain
was uneven with anterior parts of the brain receiving less enzyme
than posterior regions closer to the injection site. The simplest
explanation is that enzyme diffusion limits its distribution to areas
near the injection site. However we have shown that bgal, like
many other lysosomal enzymes [18,20], can be transported by
axonal retrograde transport from the site of injection [21]. Thus
an alternative explanation is that the bgal distribution pattern
observed here is a direct result of the tropism of AAV2/1 vector
for a subset of thalamic nuclei, namely dorsal and lateral nuclei.
The faint ISH signal present in the cerebral cortex (Fig. 1G–I)
Figure 6. Effect of AAV-treatment on motor performance of
GM1 mice. (A) Rotarod testing was performed prior to injection (0
months), and then at 1, 2.5, 4, and 6 months post-injection in AAV-T
GM1 mice (N), AAV-TC GM1 (X), untreated GM1 (m), and HZ mice (X).
Open-field testing measured (B) locomotor and (C) rearing activity at
2.5 (2.5M) and 4 (4M) months post-injection in HZ (white bars),
untreated GM1 (black bars), AAV-T GM1 (light gray bars), and AAV-TC
GM1 (dark gray bars) mice. Group sizes: n=20–24 for 0 and 1 month
time points; n=14–18 for 2.5 and 4 month time points; n=10–12 for 6
month time point. Graphs represent the mean for each group at the
specified time point. Error bars correspond to 1 SEM. * p,0.05 in paired
Student’s t-test.
doi:10.1371/journal.pone.0013468.g006
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thalamic neurons that project to the cerebral cortex, similar to our
previous observation in the hippocampal system [21]. Alterna-
tively, it could be due to leakage of vector along the needle track
with subsequent transduction of cortical cells. This could explain
the intense staining observed in these cortical regions. Additional
experiments will be necessary to determine whether more
widespread transduction of thalamic nuclei leads to wider
distribution of bgal in the brain. Others have also injected AAV
vectors encoding lysosomal enzymes into the adult thalamus in
mouse models of other LSDs, but it has been done in combination
with several other targets, and thus it is difficult to assess the
contribution of thalamic transduction to the overall pattern of
enzyme distribution in the CNS [37,44,45]. Recently, Kells and
colleagues showed that thalamic infusion of an AAV2 vector
encoding GDNF resulted in extensive distribution of this growth
factor to the frontal cortex [46]. These results support the notion
that AAV-mediated genetic modification of thalamus may indeed
be an effective approach to distribute other secreted therapeutic
proteins to large regions of the brain.
The main finding from our studies is that bilateral injections of
AAV vector in adult GM1 mice lead to sustained reduction of
GM1-ganglioside and GA1 content to nearly normal levels in most
CNS structures analyzed. The spinal cord was an exception,
however, as GM1 levels were reduced to only ,50% of the levels
found in age-matched untreated GM1 mice. Both groups of AAV-
treated mice survived significantly longer than untreated GM1
mice, with the group receiving bilateral injection of AAV vector in
the thalamus and DCN (AAV-TC group) surviving until 1 year of
age. Nonetheless the motor performance of both groups of AAV-
treated GM1 mice declined over time and was indistinguishable
from that of age-matched untreated GM1 mice. According to our
neurochemical analysis, combined bilateral injection into thalamus
and DCN (AAV-TC group) is effective in restoring GM1-
ganglioside level to normal and eliminating GA1 glycosphingolipid
in the cerebellum, while bilateral thalamic injections (AAV-T
group) lead to partial correction (Fig. 3D, light gray bars), despite
achieving enzymatic activity levels comparable to those in
cerebellum of HZ mice (Fig. 1D, light gray bars) (This apparent
paradox is addressed below). The effect on lipid content in other
CNS structures is comparable in both treatment groups. The
difference in median survival between AAV-T and AAV-TC GM1
mice suggests that disease progression in the cerebellum is a
contributing factor to the phenotype in GM1 mice. Previous
studies have shown that the earliest and most profound changes in
neuroinflammatory markers and cytokine production are found in
cerebellum, brainstem and spinal cord [12,13]. The unexpected
finding in this study was that GM1-ganglioside and GA1 levels in
the spinal cord were essentially the same in both groups of AAV-
treated mice. bgal activity in the spinal cord of both groups of
AAV-treated GM1 mice was comparable at all time points
analyzed at approximately 50% of enzymatic activity in HZ spinal
cord (same observation as in the cerebellum of AAV-T GM1
mice). This level of enzymatic activity should be sufficient to
completely correct lysosomal storage in the spinal cord. This
apparent paradox may be explained by transport of bgal from
injected structures in the brain to a relatively small subset of cells in
the spinal cord where bgal activity reaches high levels and skews
the total enzymatic activity in the tissue. The fact that we do not
observe normalization of GM1-ganglioside level and elimination
of GA1 glycosphingolipid suggests that secondary distribution of
enzyme to other cells may be inefficient. Our present observation
that injection of an AAV vector into DCN does not improve
significantly lysosomal storage in the spinal cord is surprising.
Previous studies have shown that AAV-mediated gene transfer to
DCN in mice is an effective approach to supply lysosomal enzymes
and growth factors to the spinal cord [23,24]. Moreover this target
has also been utilized in several studies of AAV-mediated gene
delivery to the adult brain in mouse models of other LSDs, but also
in the context of multi-target injections [37,44,47], and thus
difficult to discern the contribution of AAV-transduced DCN to
the overall therapeutic effect. Several explanations are possible for
Figure 7. Effect of AAV treatment on visual function in GM1
mice. Visual evoked potentials were measured in (A) wild type, (B) HZ,
(C) untreated GM1, (D) AAV-T GM1, and (E) AAV-TC GM1 mice. Group
sizes are indicated on the graphs. (C–E) Gray lines show the results for
each mouse in the group. Black lines represent the group average.
doi:10.1371/journal.pone.0013468.g007
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target, and transduction of other cerebellar regions is sufficient to
supply the cerebellum with therapeutic levels of bgal, but
inadequate for axonal transport of enzyme to the spinal cord; 2)
differences in vector preparation/purification method that could
affect its tropism, similar to the effect reported for other AAV
serotypes [48]; 3) severity of spinal cord involvement may be
disease-specific, and in GM1 mice it appears to be one of the first
structures in the CNS where alterations are detected [12,13]; 4)
higher levels of bgal may be necessary in the spinal cord of GM1
mice to achieve therapeutic correction compared to the amount of
enzyme necessary in other mouse models of LSDs. Although we
documented nearly normal GM1-ganglioside levels and complete
elimination of GA1 in cerebrum (cortex, brainstem and subcortical
structures) and cerebellum of AAV-TC GM1 mice at 4 months
post-injection (5.5 to 6 months of age), these glycosphingolipids
remained elevated in the spinal cord (2.2-fold above normal).
Since motor performance was essentially indistinguishable from
age matched untreated GM1 mice, disease progression in the
spinal may be responsible for the progressive decline in motor
performance of AAV-treated GM1 mice in the present study.
Myelin loss has been reported in patients and animal models of
GM1- gangliosidosis [41,42]. Previously we have shown that
intracerebroventricular injection of an AAV2/1-CBA-bgal vector
in neonatal GM1 mice restored cerebrosides, which are myelin-
enriched lipids, to normal levels in the cerebrum at 3 months of
age [17]. The concentration of cerebrosides is directly propor-
tional to the amount of myelin and has been used as a myelin
marker in remyelination studies in mice [49,50,51]. Our results
further document the presence of a biochemical alteration in GM1
mouse myelin, and suggest that AAV-treatment partially corrects
it (Table 1). Previous studies have shown that the timing of
intervention is a critical parameter to prevent axonal degeneration
in classical late infantile neuronal ceroid lipofuscinosis mice, where
early treatment extends considerably the longevity of AAV-treated
mice [44]. We have performed additional studies in 4 week-old
Figure 8. Presence of b-galactosidase activity in the retina of AAV-treated GM1-gangliosidosis mice. The eye was collected at the
humane endpoint or 1 year of age, and bgal activity assessed by X-gal staining at pH 5.0 of histological sections from: (A) Heterozygote mice;
(B) Untreated GM1 mice; (C) GM1 mice injected bilaterally in the thalamus (AAV-T group); (D) GM1 mice injected bilaterally in the thalamus and deep
cerebellar nuclei (AAV-TC group). Sections were counterstained with Nuclear Fast Red reagent. Abbreviations: GCL- ganglion cell layer; INL – inner
nuclear layer; ONL – outer nuclear layer. Magnification – 2006.
doi:10.1371/journal.pone.0013468.g008
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same dose of AAV2/1-CBA-mbgal vector used in this study (with
and without i.v. infusion of liver-specific AAV vector) to test this
possibility, but did not observe any improvement in motor
performance compared to age matched untreated GM1 mice
(data not shown).
A potentially important observation in this study was the
apparent preservation of some visual function in AAV-treated
GM1 mice beyond 6 months of age, while age-matched untreated
GM1 control mice did not respond to visual stimuli, as previously
described [28]. Also the observation of normal peak implicit times
with reduced amplitudes in the averaged responses in AAV-
treated mice suggests that some (but not all) cells in the retina may
have retained normal function. Since retinal ganglion cells project
to the lateral geniculate nucleus in the thalamus, and this region
appeared to express high levels of bgal (as indicated by some of the
darkest X-gal staining anywhere in the brain – See Fig. 1), it is
possible that some enzyme and/or AAV vector may have been
transported via retrograde axonal transport to the retina. The
histological evidence of bgal activity in the retinal ganglion cell
layer of AAV-treated GM1 mice supports this notion, and could
be the basis for preservation of some visual function in these mice.
The effectiveness of transport of lysosomal enzymes and/or AAV
vector from the thalamus to the eye requires additional
experiments to characterize visual function in detail (electroreti-
nograms, VEP and acuity) over time, and correlate it to GM1-
ganglioside levels and histopathology in the retina.
Although it is possible that storage in other structures in the
CNS, or remaining myelin deficits, may be involved in the long-
term phenotype observed in AAV-treated GM1 mice, the
symptoms that were displayed throughout the experiment are
consistent with spinal cord involvement. Thus we hypothesize that
to achieve long-term survival of GM1 mice with stable or
improved motor performance, it will be necessary to devise a
strategy to effectively address disease progression in the spinal
cord. Several recent studies have shown that infusion of
recombinant lysosomal enzymes into the cerebral spinal fluid via
the lateral ventricles or intrathecally, is an effective approach to
reach therapeutic levels throughout the CNS [52,53,54]. Also
intracerebroventricular and intrathecal infusion of AAV vectors
appear to be effective in delivering therapeutic levels of lysosomal
enzymes to many regions of the CNS in various mouse LSD
models [55,56]. Combination of bilateral thalamic injections with
one of these modalities may be an effective way to achieve
complete correction throughout the CNS. Other targets in the
CNS such as the ventral tegmental area (VTA) [22] and external
capsule (EC) [57] appear to be highly effective to achieve
widespread distribution of lysosomal enzymes in the brain after
a single injection of an AAV vector. Rigorous studies will be
necessary to compare the effectiveness of different AAV vector
engineered enzyme producing centers in the brain (thalamus,
VTA, EC) to achieve global distribution of those enzymes
throughout the adult GM1 mouse CNS. To our knowledge this
is the first study demonstrating the potential of thalamic gene
delivery to achieve global distribution of a lysosomal enzyme
throughout the mouse cerebrum. Our studies suggest that the
thalamus can be used as a central node in a ‘built-in’ network for
widespread distribution of lysosomal enzymes, and possibly other
secreted therapeutic proteins throughout the cerebrum.
Supporting Information
Table S1 Cortical ganglioside distribution in adult GM1 Mice, 1
month post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s001 (0.03 MB
XLS)
Table S2 Cortical ganglioside distribution in adult GM1 mice, 4
months post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s002 (0.03 MB
XLS)
Table S3 Cortical ganglioside distribution in adult GM1 mice,
at endpoint or 10 months post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s003 (0.03 MB
XLS)
Table S4 Brainstem+subcortical structures ganglioside distribu-
tion in adult GM1 mice, 1 month post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s004 (0.03 MB
XLS)
Table S5 Brainstem+subcortical structures ganglioside distribu-
tion in adult GM1 mice, 4 months post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s005 (0.03 MB
XLS)
Table S6 Cerebellar ganglioside distribution in adult GM1
mice, 1 month post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s006 (0.03 MB
XLS)
Table S7 Cerebellar ganglioside distribution in adult GM1
mice, 4 month post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s007 (0.03 MB
XLS)
Table S8 Cerebellar ganglioside distribution in adult GM1
mice, at endpoint or 10 months post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s008 (0.03 MB
XLS)
Table S9 Spinal Cord ganglioside distribution in adult GM1
mice, 1 month post AAV in injection.
Found at: doi:10.1371/journal.pone.0013468.s009 (0.03 MB
XLS)
Table S10 Spinal Cord ganglioside distribution in adult GM1
mice, 4 month post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s010 (0.03 MB
XLS)
Figure 9. Kaplan-Meier survival analysis of AAV-treated GM1
mice. Untreated GM1 (KO, black line), PBS-treated GM1 (PBS, bold
dashed line), heterozygote (HZ, dashed line), AAV-T GM1 (light gray
line), and AAV-TC GM1 (dark gray line) mice were allowed to survive
until the humane endpoint defined by .20% body weight loss, or 52
weeks of age. N=8–12 per group.
doi:10.1371/journal.pone.0013468.g009
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mice, at endpoing or 10 month post AAV ic injection.
Found at: doi:10.1371/journal.pone.0013468.s011 (0.03 MB
XLS)
Acknowledgments
We would like to thank our colleague Douglas R. Martin (Scott-Ritchey
Research Center, Auburn University) for helpful suggestions and critical
reading of the manuscript.
Author Contributions
Conceived and designed the experiments: RCB MLDB TS MSE.
Performed the experiments: RCB MLDB SGL LAT MAS MSE. Analyzed
the data: RCB MLDB SGL MAS TS MSE. Contributed reagents/
materials/analysis tools: AdA. Wrote the paper: RCB MLDB MSE.
References
1. Okada S, O’Brien JS (1968) Generalized gangliosidosis: beta-galactosidase
deficiency. Science 160: 1002–1004.
2. O’Brien JS, Stern MB, Landing BH, O’Brien JK, Donnell GN (1965)
Generalized Gangliosidosis: Another Inborn Error of Ganglioside Metabolism?
Am J Dis Child 109: 338–346.
3. Suzuki Y, Oshima A, Nanba E (2001) b-galactosidase deficiency (b-
galactosidosis): GM1 gangliosidosis and Morquio B disease. In: Scriver CR,
Beaudet AL, Sly WS, Valle D, eds. The Online Metabolic & Molecular Basis of
Inherited Diseases. New York: McGraw-Hill. pp 3775–3810.
4. Bieber FR, Mortimer G, Kolodny EH, Driscoll SG (1986) Pathologic findings in
fetal GM1 gangliosidosis. Arch Neurol 43: 736–738.
5. Kudoh T, Kikuchi K, Nakamura F, Yokoyama S, Karube K, et al. (1978)
Prenatal diagnosis of GM1-gangliosidosis: biochemical manifestations in fetal
tissues. Hum Genet 44: 287–293.
6. Hahn CN, del Pilar Martin M, Schroder M, Vanier MT, Hara Y, et al. (1997)
Generalized CNS disease and massive GM1-ganglioside accumulation in mice
defective in lysosomal acid beta-galactosidase. Hum Mol Genet 6: 205–211.
7. Matsuda J, Suzuki O, Oshima A, Ogura A, Noguchi Y, et al. (1997) Beta-
galactosidase-deficient mouse as an animal model for GM1-gangliosidosis.
Glycoconj J 14: 729–736.
8. Kasperzyk JL, El-Abbadi MM, Hauser EC, D’Azzo A, Platt FM, et al. (2004) N-
butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a
mouse model of GM1 gangliosidosis. J Neurochem 89: 645–653.
9. Hauser EC, Kasperzyk JL, d’Azzo A, Seyfried TN (2004) Inheritance of
lysosomal acid b-galactosidase activity and gangliosides in crosses of DBA/2J
and knockout mice. Biochem Genetics 42: 241–257.
10. Sano R, Annunziata I, Patterson A, Moshiach S, Gomero E, et al. (2009) GM1-
ganglioside accumulation at the mitochondria-associated ER membranes links
ER stress to Ca(2+)-dependent mitochondrial apoptosis. Mol Cell 36: 500–511.
11. Tessitore A, del PMM, Sano R, Ma Y, Mann L, et al. (2004) GM1-ganglioside-
mediated activation of the unfolded protein response causes neuronal death in a
neurodegenerative gangliosidosis. Mol Cell 15: 753–766.
12. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, et al.
(2003) Central nervous system inflammation is a hallmark of pathogenesis in
mouse models of GM1 and GM2 gangliosidosis. Brain 126: 974–987.
13. Sano R, Tessitore A, Ingrassia A, d’Azzo A (2005) Chemokine-induced
recruitment of genetically modified bone marrow cells into the CNS of GM1-
gangliosidosis mice corrects neuronal pathology. Blood 106: 2259–2268.
14. Elliot-Smith E, Speak AO, Lloyd-Evans E, Smith DA, van der Spoel AC, et al.
(2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1
gangliosidosis. Mol Genet Metab 94: 204–211.
15. Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases.
Mol Ther 13: 839–849.
16. Vite CH, McGowan JC, Niogi SN, Passini MA, Drobatz KJ, et al. (2005)
Effective gene therapy for an inherited CNS disease in a large animal model.
Ann Neurol 57: 355–364.
17. Broekman ML, Baek RC, Comer LA, Fernandez JL, Seyfried TN, et al. (2007)
Complete Correction of Enzymatic Deficiency and Neurochemistry in the
GM1-gangliosidosis Mouse Brain by Neonatal Adeno-associated Virus-mediated
Gene Delivery. Mol Ther 15: 30–37.
18. Passini MA, Lee EB, Heuer GG, Wolfe JH (2002) Distribution of a lysosomal
enzyme in the adult brain by axonal transport and by cells of the rostral
migratory stream. J Neurosci 22: 6437–6446.
19. Hennig AK, Levy B, Ogilvie JM, Vogler CA, Galvin N, et al. (2003) Intravitreal
gene therapy reduces lysosomal storage in specific areas of the CNS in
mucopolysaccharidosis VII mice. J Neurosci 23: 3302–3307.
20. Luca T, Givogri MI, Perani L, Galbiati F, Follenzi A, et al. (2005) Axons
mediate the distribution of arylsulfatase A within the mouse hippocampus upon
gene delivery. Mol Ther 12: 669–679.
21. Broekman ML, Tierney LA, Benn C, Chawla P, Cha JH, et al. (2009)
Mechanisms of distribution of mouse beta-galactosidase in the adult GM1-
gangliosidosis brain. Gene Ther 16: 303–308.
22. Cearley CN, Wolfe JH (2007) A single injection of an adeno-associated virus
vector into nuclei with divergent connections results in widespread vector
distribution in the brain and global correction of a neurogenetic disease.
J Neurosci 27: 9928–9940.
23. Dodge JC, Clarke J, Song A, Bu J, Yang W, et al. (2005) Gene transfer of human
acid sphingomyelinase corrects neuropathology and motor deficits in a mouse
model of Niemann-Pick type A disease. Proc Natl Acad Sci U S A 102:
17822–17827.
24. Dodge JC, Haidet AM, Yang W, Passini MA, Hester M, et al. (2008) Delivery of
AAV-IGF-1 to the CNS Extends Survival in ALS Mice Through Modification of
Aberrant Glial Cell Activity. Mol Ther.
25. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, et al.
(2005) Factor IX variants improve gene therapy efficacy for hemophilia B. Blood
105: 2316–2323.
26. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M (2006) Adeno-
associated virus vectors serotyped with AAV8 capsid are more efficient than
AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
Neuroscience 138: 501–510.
27. Denny CA, Kasperzyk JL, Gorham KN, Bronson RT, Seyfried TN (2006)
Influence of caloric restriction on motor behavior, longevity, and brain lipid
composition in Sandhoff disease mice. J Neurosci Res 83: 1028–1038.
28. Denny CA, Alroy J, Pawlyk BS, Sandberg MA, d’Azzo A, et al. (2007)
Neurochemical, morphological, and neurophysiological abnormalities in retinas
of Sandhoff and GM1 gangliosidosis mice. J Neurochem 101: 1294–1302.
29. Kasperzyk JL, d’Azzo A, Platt FM, Alroy J, Seyfried TN (2005) Substrate
reduction therapy reduces ganglioside content in postnatal cerebrum-brainstem
and cerebellum in a mouse model of GM1 gangliosidosis. J Lipid Res.
30. Baek RC, Kasperzyk JL, Platt FM, Seyfried TN (2008) N-butyldeoxygalacto-
nojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff
disease mice. Neurochem Int 52: 1125–1133.
31. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation
and purification of total lipides from animal tissues. J Biol Chem 226: 497–509.
32. Svennerholm L (1957) Quantitative estimation of sialic acids II. A colorimetric
resorcinol-hydrochloric acid method. Biochim Biophys Acta 24: 604–611.
33. Williams MA, McCluer RH (1980) The use of Sep-Pak C18 cartridges during
the isolation of gangliosides. J Neurochem 35: 266–269.
34. Seyfried TN, Bernard D, Mayeda F, Macala L, Yu RK (1984) Genetic analysis
of cerebellar lipids in mice susceptible to audiogenic seizures. Exp Neurol 84:
590–595.
35. Seyfried TN, Yu RK, Miyazawa N, Lai YL (1982) Retinal gangliosides in RCS
mutant rats. J Neurochem 39: 277–279.
36. Bookout AL, Mangelsdorf DJ (2003) Quantitative real-time PCR protocol for
analysis of nuclear receptor signaling pathways. Nucl Recept Signal 1: e012.
37. Passini MA, Bu J, Fidler JA, Ziegler RJ, Foley JW, et al. (2007) Combination
brain and systemic injections of AAV provide maximal functional and survival
benefits in the Niemann-Pick mouse. Proc Natl Acad Sci U S A 104: 9505–9510.
38. Goldman JE, Hirano M, Yu RK, Seyfried TN (1984) GD3 ganglioside is a
glycolipid characteristic of immature neuroectodermal cells. J Neuroimmunol 7:
179–192.
39. Matthieu JM, Widmer S, Herschkowitz N (1973) Biochemical changes in mouse
brain composition during myelination. Brain Res 55: 391–402.
40. Norton WT, Poduslo SE (1973) Myelination in rat brain: changes in myelin
composition during brain maturation. J Neurochem 21: 759–773.
41. Kaye EM, Alroy J, Raghavan SS, Schwarting GA, Adelman LS, et al. (1992)
Dysmyelinogenesis in animal model of GM1 gangliosidosis. Pediatr Neurol 8:
255–261.
42. Folkerth RD, Alroy J, Bhan I, Kaye EM (2000) Infantile G(M1) gangliosidosis:
complete morphology and histochemistry of two autopsy cases, with particular
reference to delayed central nervous system myelination. Pediatr Dev Pathol 3:
73–86.
43. Kasama T, Taketomi T (1986) Abnormalities of cerebral lipids in GM1-
gangliosidoses, infantile, juvenile, and chronic type. Jpn J Exp Med 56: 1–11.
44. Cabrera-Salazar MA, Roskelley EM, Bu J, Hodges BL, Yew N, et al. (2007)
Timing of therapeutic intervention determines functional and survival outcomes
in a mouse model of late infantile batten disease. Mol Ther 15: 1782–1788.
45. Husain T, Passini MA, Parente MK, Fraser NW, Wolfe JH (2009) Long-term
AAV vector gene and protein expression in mouse brain from a small pan-
cellular promoter is similar to neural cell promoters. Gene Ther 16: 927–932.
46. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, et al. (2009) Efficient gene
therapy-based method for the delivery of therapeutics to primate cortex. Proc
Natl Acad Sci U S A 106: 2407–2411.
47. Cachon-Gonzalez MB, Wang SZ, Lynch A, Ziegler R, Cheng SH, et al. (2006)
Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc
Natl Acad Sci U S A 103: 10373–10378.
AAV Thalamic Gene Delivery
PLoS ONE | www.plosone.org 15 October 2010 | Volume 5 | Issue 10 | e1346848. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP (2008) AAV8,
9, Rh10, Rh43 Vector Gene Transfer in the Rat Brain: Effects of Serotype,
Promoter and Purification Method. Mol Ther 16: 89–96.
49. Morell P, Quarles RH (1999) Myelin formation, structure, and biochemistry. In:
Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, eds. Basic
Neurochemistry. sixth ed. New York: Lippincott-Raven.
50. Jurevics H, Largent C, Hostettler J, Sammond DW, Matsushima GK, et al.
(2002) Alterations in metabolism and gene expression in brain regions during
cuprizone-induced demyelination and remyelination. J Neurochem 82:
126–136.
51. Seyfried TN, Yu RK (1980) Heterosis for brain myelin content in mice. Biochem
Genet 18: 1229–1237.
52. Dickson P, McEntee M, Vogler C, Le S, Levy B, et al. (2007) Intrathecal enzyme
replacement therapy: successful treatment of brain disease via the cerebrospinal
fluid. Mol Genet Metab 91: 61–68.
53. Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, et al. (2008)
Intraventricular Enzyme Replacement Improves Disease Phenotypes in a Mouse
Model of Late Infantile Neuronal Ceroid Lipofuscinosis. Mol Ther.
54. Dodge JC, Clarke J, Treleaven CM, Taksir TV, Griffiths DA, et al. (2009)
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS
manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol 215:
349–357.
55. Liu G, Martins I, Wemmie JA, Chiorini JA, Davidson BL (2005) Functional
correction of CNS phenotypes in a lysosomal storage disease model using adeno-
associated virus type 4 vectors. J Neurosci 25: 9321–9327.
56. Watson G, Bastacky J, Belichenko P, Buddhikot M, Jungles S, et al. (2006)
Intrathecal administration of AAV vectors for the treatment of lysosomal storage
in the brains of MPS I mice. Gene Ther 13: 917–925.
57. Lattanzi A, Neri M, Maderna C, di Girolamo I, Martino S, et al. Widespread
enzymatic correction of CNS tissues by a single intracerebral injection of
therapeutic lentiviral vector in leukodystrophy mouse models. Hum Mol Genet
19: 2208–2227.
AAV Thalamic Gene Delivery
PLoS ONE | www.plosone.org 16 October 2010 | Volume 5 | Issue 10 | e13468